Skip to main content
. 2018 Aug 27;19(9):2540. doi: 10.3390/ijms19092540

Table 3.

OS data of gliovac in comparison to bevacizumab studies. Published Bevacizumab monotherapy studies from: Taal et al., 2014 [33], Field et al., 2015 [34], Heiland et al., 2016 [35].

6 mo OS 9 mo OS 12 mo OS
Study Treatment All Pts (%) All Pts (%) All Pts (%)
ERC 1671 ERC 1671 100 80 40
Taal (BELOB) BEV
Monotherapy
62 45 26
Field (CABARET) 61 39 24
Heiland (Freiburg, Germany) 18 12 10